Iovance Biotherapeutics
Stock Forecast, Prediction & Price Target
Iovance Biotherapeutics (IOVA) stock Price Target by analysts
$17
Potential upside: 551.34%
Iovance Biotherapeutics price prediction
What is Iovance Biotherapeutics stock analysts` prediction?
Iovance Biotherapeutics stock forecast: Based on 1 Wall Street analysts` predicted price targets for Iovance Biotherapeutics in the last 3 months, the avarage price target is $17, with a high forecast of $NaN. The average price target represents a 551.34% change from the last price of $2.61.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Iovance Biotherapeutics stock Price Target by analysts
Full breakdown of analysts given Iovance Biotherapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
David Dai UBS | 0% 0/1 | 11 months ago | $17 551.34% upside | $9.82 | StreetInsider | Previous targets (0) |
Benjamin Burnett Stifel Nicolaus | 0% 0/3 | about 1 year ago | $23 781.22% upside | $3.97 | StreetInsider | Previous targets (2) |
Colleen Kusy Robert W. Baird | 0% 0/2 | about 1 year ago | $24 819.54% upside | $3.97 | StreetInsider | Previous targets (1) |
Joseph Catanzaro Piper Sandler | 0% 0/3 | about 1 year ago | $10 283.14% upside | $9.25 | StreetInsider | Previous targets (2) |
Reni Benjamin JMP Securities | 0% 0/1 | about 1 year ago | $23 781.22% upside | $8 | TheFly | Previous targets (0) |
Benjamin Burnett Stifel Nicolaus | 0% 0/3 | over 1 year ago | $28 972.79% upside | $8.88 | StreetInsider | Previous targets (2) |
Joseph Catanzaro Piper Sandler | 0% 0/3 | over 1 year ago | $19 627.96% upside | $14.21 | StreetInsider | Previous targets (2) |
Madhu Kumar Goldman Sachs | 100% 1/1 | over 2 years ago | $6 129.88% upside | $7.17 | TheFly | Previous targets (0) |
Joseph Catanzaro Piper Sandler | 0% 0/3 | almost 3 years ago | $11 321.45% upside | $6.62 | TheFly | Previous targets (2) |
Michael Ulz Robert W. Baird | 0% 0/1 | about 3 years ago | $25 857.85% upside | $11.5 | Pulse 2.0 | Previous targets (0) |
Unknown Goldman Sachs | N/A | about 3 years ago | $18 589.65% upside | $11.04 | Benzinga | N/A |
Unknown Stifel Nicolaus | N/A | over 3 years ago | $13 398.08% upside | $6.94 | Benzinga | N/A |
Unknown Chardan Capital | N/A | over 3 years ago | $31 1087.73% upside | $6.95 | Benzinga | N/A |
Unknown Goldman Sachs | N/A | over 3 years ago | $64 2352.10% upside | $14.51 | Benzinga | N/A |
Colleen Kusy Robert W. Baird | 0% 0/2 | over 3 years ago | $34 1202.68% upside | $18.23 | Pulse 2.0 | Previous targets (1) |
Colleen M. Kusy Robert W. Baird | 0% 0/1 | over 3 years ago | $30 1049.42% upside | $16.56 | TheFly | Previous targets (0) |
Benjamin Burnett Stifel Nicolaus | 0% 0/3 | over 3 years ago | $25 857.85% upside | $15.04 | Pulse 2.0 | Previous targets (2) |
Nick Abbott Wells Fargo | 0% 0/1 | over 3 years ago | $25 857.85% upside | $16.82 | TheFly | Previous targets (0) |
Peter Lawson Barclays | 0% 0/1 | over 4 years ago | $40 1432.56% upside | $16.33 | TheFly | Previous targets (0) |
Iovance Biotherapeutics Financial Estimates
Iovance Biotherapeutics Revenue Estimates
Iovance Biotherapeutics EBITDA Estimates
Iovance Biotherapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $1.18M 0% | Avg: $391.34M Low: $122.72M High: $559.88M avg. 32813.84% | Avg: $694.42M Low: $198.21M High: $1.02B avg. 77.44% | Avg: $1.04B Low: $297.74M High: $1.54B avg. 50.21% | Avg: $1.37B Low: $392.37M High: $2.03B avg. 31.78% |
Net Income
% change YoY
| $-327.82M N/A | $-389.92M -18.94% | $-444.03M -13.87% | Avg: $-231.24M Low: $-357.39M High: $75.24M avg. 47.92% | Avg: $-38.33M Low: $-270.40M High: $284.50M avg. 83.42% | Avg: $183.79M Low: $13.06M High: $298.44M avg. 579.48% | Avg: $366.80M Low: $26.07M High: $595.60M avg. 99.57% |
EBITDA
% change YoY
| $-342.70M N/A | $-398.87M -16.39% | $-427.43M -7.15% | Avg: $234.80M Low: $73.63M High: $335.92M avg. 154.93% | Avg: $416.65M Low: $118.93M High: $616.57M avg. 77.44% | Avg: $625.86M Low: $178.64M High: $926.17M avg. 50.21% | Avg: $824.77M Low: $235.42M High: $1.22B avg. 31.78% |
EPS
% change YoY
| -$2.14 N/A | -$2.45 -14.48% | -$1.89 22.85% | Avg: -$0.71 Low: -$1.52 High: $0.32 avg. 62.32% | Avg: -$0.03 Low: -$1.15 High: $1.21 avg. 95.58% | Avg: $0.78 Low: $0.06 High: $1.27 avg. 2587.01% | Avg: $1.56 Low: $0.11 High: $2.53 avg. 99.57% |
Operating Expenses
% change YoY
| $342.70M N/A | $398.87M 16.39% | $450.99M 13.06% | Avg: $5.87B Low: $1.84B High: $8.41B avg. 1203.43% | Avg: $10.43B Low: $2.97B High: $15.43B avg. 77.44% | Avg: $15.66B Low: $4.47B High: $23.18B avg. 50.21% | Avg: $20.64B Low: $5.89B High: $30.55B avg. 31.78% |
FAQ
What is Iovance Biotherapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 202.60% in 2025-2028.
We have gathered data from 9 analysts. Their low estimate is -357.39M, average is -231.24M and high is 75.24M.
What is Iovance Biotherapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 8243.32% in 2025-2028.
We have gathered data from 9 analysts. Their low revenue estimate is $122.72M, average is $391.34M and high is $559.88M.
What is Iovance Biotherapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 711.12% in 2025-2028.
We have gathered data from 9 analysts. Their low earnings per share estimate is -$1.52, average is -$0.71 and high is $0.32.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering Iovance Biotherapeutics stock. The most successful analyst is David Dai.